<DOC>
	<DOCNO>NCT00340184</DOCNO>
	<brief_summary>The purpose study determine whether post-operative concurrent chemoradiation paclitaxel/carboplatin effective safe treatment high risk cervical cancer patient .</brief_summary>
	<brief_title>A Safety Efficacy CCRT With Paclitaxel/Carboplatin Adjuvant Therapy Post-operative Cervical Cancer Patients</brief_title>
	<detailed_description>Stage Ib IIa cervical cancer treat effectively either radioterapy radical hysterectomy plus pelvic lymph node dissection . However , several pathological risk factor identify compromise treatment outcome . They include lymph node metastasis , involvement vaginal resection margin , parametrial invasion . In patient , postoperative RT commonly recommend demonstrate improve local control , survival rate . Recently , It report additon concurrent chemotherapy postoperative RT reduce pelvic failure enhance progression free survival . In addition , paclitaxel/platinum combination chemotherapy demonstrate superior progression-free survical single agent platinum primary treatment stage IV recurrent cervical cancer . Based obseration , evaluate efficacy safety CCRT paclitaxel/carboplatin patient postoperative high risk factor .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients undertaken radical hysterectomy diagnosis invasive cervical cancer IbIIa ( nonsmall cell type ) Patients must least one follow risk factor ; pelvic lymph node involvemet , involvement vaginal resection margin , parametrial invasion . Patients must GOG performance 0 , 1 , 2 . Patients must expect life span 6 month . Patients peripheral neurotoxicity grade 2 CTC criterion . Patients history chemotherapy radiation treatment . Patients histologicallly proven highly suspected metastasis paraaortic lymph node . Patients history hypersensitive reaction platinum agent .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>concurrent</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>